Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

IGM Biosciences, Inc. IGMS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
43/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.75
+37.8%

IGM Biosciences, Inc. (IGMS) is a Biotechnology company in the Healthcare sector, currently trading at $1.27. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is IGMS = $2 (+37.8% upside).

Financials: revenue is $3M, +62.5%/yr average growth. Net income is $196M (loss), growing at -9.3%/yr. Net profit margin is -7308.5% (negative). Gross margin is -240.1% (+651.7 pp trend).

Balance sheet: total debt is $45M against $48M equity (Debt-to-Equity (D/E) ratio 0.94, moderate). Current ratio is 5.14 (strong liquidity). Debt-to-assets is 17%. Total assets: $266M.

Analyst outlook: 8 / 18 analysts rate IGMS as buy (44%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 15/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$1.75
▲ 37.8% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for IGM Biosciences, Inc., the average price target is $1.75, with a high forecast of $2.00, and a low forecast of $1.50.
Highest Price Target
$2.00
Average Price Target
$1.75
Lowest Price Target
$1.50

IGMS SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 15/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IGMS

✓
VALUE Pass
90/100
IGMS trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying +57.5% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
IGMS: +62.5%/yr revenue is, -9.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet IGMS: Debt-to-Equity (D/E) ratio 0.94 (moderate), Current ratio is 5.14 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
15/100
IGMS: Gross margin is -240.1% (+651.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 8 / 18 analysts rate IGMS as buy (44%). Analyst consensus target is $2 (+57.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
IGMS: Net profit margin is -7308.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.92-22.5
Volume1.59M
Avg Volume (30D)634.44K
Market Cap$77.5M
Beta (1Y)0.59
Share Statistics
EPS (TTM)-3.24
Shares Outstanding$60.51M
IPO Date2019-09-18
Employees149
CEOMary Beth Harler
Financial Highlights & Ratios
Revenue (TTM)$2.68M
Gross Profit$-6.43M
EBITDA$-199.47M
Net Income$-195.8M
Operating Income$-208.58M
Total Cash$183.79M
Total Debt$45.19M
Net Debt$18.69M
Total Assets$265.71M
Price / Earnings (P/E)-0.4
Price / Sales (P/S)28.93
Analyst Forecast
1Y Price Target$1.75
Target High$2.00
Target Low$1.50
Upside+37.8%
Rating ConsensusHold
Analysts Covering18
Buy 44% Hold 56% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS4495851085

Price Chart

Track all markets on TradingView
IGMS
IGM Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.92 52WK RANGE 22.50

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message